These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. Aziz NAAM; George RF; El-Adl K; Mahmoud WR Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374 [TBL] [Abstract][Full Text] [Related]
14. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
15. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors. Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519 [TBL] [Abstract][Full Text] [Related]